Join to View Full Profile
1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Dr. Skoulidis is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Aristotle University of Thessaloniki School of MedicineClass of 2000
Certifications & Licensure
FL State Medical License 2021 - Present
TX State Medical License 2018 - 2026
OK State Medical License 2020 - 2021
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Clinical Trials
Publications & Presentations
PubMed
- Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summary.Adrianus Johannes de Langen, Melissa L Johnson, Julien Mazieres, Anne-Marie C Dingemans, Giannis Mountzios
Future Oncology. 2025-04-01 - Receptor Tyrosine Kinase Fusion-Mediated Resistance to EGFR TKI in EGFR-Mutant NSCLC: A Multi-Center Analysis and Literature Review.Yang Xia, Kaiwen Wang, Jing Zhao, Zhaohui Arter, Yongchang Zhang
Journal of Thoracic Oncology. 2025-04-01 - Impact of Co-mutations and Transcriptional Signatures in Non-Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial.Marcelo V Negrao, Alvaro G Paula, David Molkentine, Laura Hover, Monique Nilsson
Clinical Cancer Research. 2025-03-17
Lectures
- Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell l...2019 ASCO Annual Meeting - 6/1/2019
- Association of STK11/LKB1 mutations with primary resistance to PD-1/PD-L1 axis blockade in PD-L1 positive non-squamous NSCLC.2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Press Mentions
Should First-Line Dual Checkpoint Blockade Be Used for NSCLC with Specific Mutations?October 24th, 2024- Dual Immunotherapy plus Chemotherapy Benefits Specific Subset of Patients with Lung CancerOctober 9th, 2024
- MD Anderson Research Highlights for July 11, 2024July 11th, 2024
- Join now to see all
Grant Support
- Targeting non-small cell lung cancer cells and the adverse tumor microenvironment with a small-molecule STAT3 inhibitorUNIVERSITY OF TX MD ANDERSON CAN CTR2023–2028
- Targeting non-small cell lung cancer cells and the adverse tumor microenvironment with a small-molecule STAT3 inhibitorUNIVERSITY OF TX MD ANDERSON CAN CTR2023–2028
- Dissecting and targeting tumor-TME crosstalk to forestall acquired KRASG12C inhibitor resistance in NSCLC.UNIVERSITY OF TX MD ANDERSON CAN CTR2023–2028
- Dissecting and targeting mechanisms of genomic instability-triggered immune evasion in RBM10-deficient non-small cell lung cancerUNIVERSITY OF TX MD ANDERSON CAN CTR2023–2028
- Targeting non-small cell lung cancer cells and the adverse tumor microenvironment with a small-molecule STAT3 inhibitorUNIVERSITY OF TX MD ANDERSON CAN CTR2023–2028
- Understanding and harnessing immune-modulatory effects of covalent KRASG12C inhibitors in KRASG12C-mutant non-small cell lung cancerUNIVERSITY OF TX MD ANDERSON CAN CTR2021–2026
- Understanding and harnessing immune-modulatory effects of covalent KRASG12C inhibitors in KRASG12C-mutant non-small cell lung cancerUNIVERSITY OF TX MD ANDERSON CAN CTR2021–2026
- Understanding and harnessing immune-modulatory effects of covalent KRASG12C inhibitors in KRASG12C-mutant non-small cell lung cancerUNIVERSITY OF TX MD ANDERSON CAN CTR2021–2026
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
